34158-71-9

Basic information

• Product Name: 3-Chlorobenzaldehyde oxime
• Synonyms: 3-Chlorobenzaldoxime;Benzaldehyde, 3-chloro-, oxime;Benzaldehyde, m-chloro-, oxime;Nsc122430
• CAS NO: 34158-71-9
• Molecular Formula: C₇H₆ClNO
• Molecular Weight: 155.5816
• Mol File: 34158-71-9.mol
• Article Data: 78

Chemical Properties

• Boiling Point: 247.1°Cat760mmHg
• Flash Point: 103.2°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 0.0139mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: 3-Chlorobenzaldehyde oxime(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chlorobenzaldehyde oxime(34158-71-9)
• EPA Substance Registry System: 3-Chlorobenzaldehyde oxime(34158-71-9)

Safety Data

• Hazardous Substances Data: 34158-71-9(Hazardous Substances Data)

Usage

General Description

3-Chlorobenzaldehyde oxime is a chemical compound with the molecular formula C7H6ClNO. It is a pale yellow solid with a melting point of around 71-73°C. 3-Chlorobenzaldehyde oxime is primarily used as a building block in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and dyes. It is also known to act as a chelating agent, forming stable complexes with metals such as copper, nickel, and cobalt. Additionally, it has been studied for its potential role in corrosion inhibition and as a ligand for catalysis in various chemical reactions. Overall, 3-Chlorobenzaldehyde oxime is a versatile and valuable chemical that finds applications in various industries.

InChI:InChI=1/C7H6ClNO/c8-7-3-1-2-6(4-7)5-9-10/h1-5,10H/b9-5+

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 96-29-7 ethyl methyl ketone oxime 
• 873-63-2 m-chlorobenzyl alcohol 
• 2972-73-8 2-(3-chlorobenzylidene)malononitrile 
• 99-61-6 3-nitro-benzaldehyde 
• 87-91-2 diethyl (2R,3R)-tartrate 
• 3717-33-7 (Z)-3-chlorobenzaldehyde oxime 
• 108-37-2 1-bromo-3-chlorobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 1309880-47-4 [(3-Chlorobenzyl)oxy]trimethylsilane 
• 18483-96-0 2-(3-chlorobenzyloxy)tetrahydro-2H-pyran 
• 5470-11-1 hydroxylamine hydrochloride 
• 4152-90-3 m-chlorobenzylamine 

Downstream Products

• 2905-65-9 methyl 3-chlorobenzoate 
• 90733-01-0 [5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-phenyl-methanone 
• 1128-76-3 3-chloro-benzoic acid ethyl ester 
• 141891-20-5 3-Chloro-benzaldehyde O-ethyl-oxime 
• 13820-15-0 3-chlorobenzonitrile oxide 
• 618-48-4 3-chlorobenzamide 
• 869496-60-6 C₁₀H₆ClNO₂ 
• 1337539-48-6 C₂₆H₃₁ClN₄O 
• 1337539-54-4 C₂₆H₃₀ClFN₄O 
• 1337539-62-4 C₂₆H₃₀Cl₂N₄O 
• 1337539-70-4 C₂₆H₃₀ClFN₄O 
• 101862-42-4 [3-(3-chloro-phenyl)-isoxazol-5-yl]-methanol 
• 41421-28-7 5-(m-chlorophenyl)tetrazole 
• 958970-82-6 2-(4-chlorophenyl)-5-(3-(3-chlorophenyl)-5-methyl-4,5-dihydroisoxazol-5-yl)-1,3,4-oxadiazole 

Relevant articles and documents

Site selective synthesis and anti-inflammatory evaluation of Spiro-isoxazoline stitched adducts of arteannuin B

A library of new spiroisoxazoline analogues of arteannuin B was synthesized through 1, 3-dipolar cycloaddition in stereoselective fashion and consequently screened for anti-inflammatory activity in RAW 264.7 macrophage cells. Three potent analogues (8i, 8 m, and 8n) were found to attenuate the LPS induced release of cytokines IL-6 and TNF-α more potently than the parent molecule. Also, the inhibition of LPS induced nitric oxide production in these cells show moderate to high efficacy. None of the three potent molecules have altered the viability of RAW 264.7 cells following 48 h incubation suggesting that the inhibition of cytokines and nitric oxide production exhibited in the cells was not due to toxicity. In addition, these compounds exhibit an IC50 range of 0.17 μM-1.57 μM and 0.09 μM-0.35 μM for the inhibition of IL-6 release and nitric oxide production respectively. The results disclose potent inhibition of pro-inflammatory mediators which are encouraging and warrant further investigations to develop new therapeutic agents for inflammatory diseases.

Design, synthesis, in vitro and in silico evaluation of new 3-phenyl-4,5-dihydroisoxazole-5-carboxamides active against drug-resistant mycobacterium tuberculosis

A new series of 3-phenyl-4,5-dihydroisoxazole-5-carboxamides were designed, synthesized, and evaluated for their potency against Mtb H37Rv. Designed molecules were synthesized by one-pot cycloaddition reaction in good to excellent yields. Anti-Tubercular evaluation of all synthesized derivatives identified 6k to be highly potent (MIC 1 μg/mL) against Mtb and drug-resistant strains. All potent derivatives were found to be non-toxic when tested against Vero cells. Also, in silico studies were employed to explore the binding patterns of designed compounds to target Mycobacterial membrane protein Large-3. All derivatives exhibited excellent binding patterns with the receptor. The excellent in silico Absorption, Distribution, Metabolism, and Excretion properties and druggability parameters positions these molecules as promising lead candidates for the future development of new drugs to treat drug-resistant Tuberculosis.

Synthesis and SAR study of simple aryl oximes and nitrofuranyl derivatives with potent activity against Mycobacterium tuberculosis

Background: Oximes and nitrofuranyl derivatives are particularly important compounds in medicinal chemistry. Thus, many researchers have been reported to possess antibacterial, antiparasitic, insecticidal and fungicidal activities. Methods: In this work, we report the synthesis and the biological activity against Mycobacterium tuberculosis H37RV of a series of fifty aryl oximes, ArCH=N-OH, I, and eight nitrofuranyl compounds, 2-nitrofuranyl-X, II. Results: Among the oximes, I: Ar = 2-OH-4-OH, 42, and I: Ar = 5-nitrofuranyl, 46, possessed the best activity at 3.74 and 32.0 μM, respectively. Also, 46, the nitrofuran compounds, II; X = MeO, 55, and II: X = NHCH2Ph, 58, (14.6 and 12.6 μM, respectively), exhibited excellent biological activities and were non-cytotoxic. Conclusion: The compound 55 showed a selectivity index of 9.85. Further antibacterial tests were performed with compound 55 which was inactive against Enterococcus faecalis, Klebisiella pneumonae, Pseudomonas aeruginosa, Staphylococcus aureus, Salmonella typhymurium and Shigel-la flexneri. This study adds important information to the rational design of new lead anti-TB drugs. Structure-activity Relationship (SAR) is reported.